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Background: The identification of disease causing, or putative disease causing, mutations in index patients with
Charcot-Marie-Tooth disease (CMT) allows for genetic testing of family members. Relevant variants identified in
index patients are of either definite, likely or uncertain pathogenicity. The main objective of this study was to make
an evaluation of the family investigations performed as part of the assessment of genetic variants of unknown
clinical significance (VUS).
Methods: Between 2004 and 2010 molecular genetic family investigations were requested for 87 family members
from 41 families harbouring PMP22dup or genetic variants in GJB1, MPZ, MFN2 and NEFL. Relatives were tested for
the family mutation and data from the requisitions were evaluated by means of statistical tools.
Results: The results within each indication category are presented and discussed in detail. Twenty-two relatives
(9 affected) from eight families were included in the segregation analyses, which invoked reclassification of three
MFN2 mutations, two of which were de novo substitutions (c.2146_2148dup, c.692C > T). One MFN2 substitution
was downgraded due to non-segregation (c.1709 A > G), and a MPZ substitution (c.103 G > A) upgraded due to
segregation with the phenotype in the family.
Conclusions: The results allow for the evaluation of the patient phenotypes ascertained in families, as opposed to
the phenotypic descriptions of index patients. They indicate that de novo MFN2 mutations are regularly found in
patients with a classical CMT2 phenotype. They also demonstrate the importance of a precise clinical and
neurophysiologic diagnosis of affected family members. This particularly applies for the examination of variants of
uncertain clinical significance. Finally, the fact that 14,6% of affected relatives tested for (probable or certain)
pathogenic mutations were mutation negative, demonstrates that clinical evaluation alone is not always sufficient
in order to determine their diagnosis. We believe that the results will aid in the estimation and planning of
resources required for the various aspects of family evaluations in CMT.
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Table 1 The 31 index patients diagnosed at our
laboratory
Classification† Gene N indexes N total
5 GJB1 10 18
PMP22dup 6
MPZ 2
4 GJB1 2 5
MPZ 2
MFN2 1
3 MPZ 3 8
NEFL 1
MFN2 4
†Classification of genetic variants in accordance with the recommendations
from the IARC Unclassified Genetic Variants Working Group; 5 = definitely
pathogenic, 4 = likely pathogenic, 3 = uncertain, 2 = likely not pathogenic,
1 = definitely not pathogenic [18].
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Charcot Marie Tooth disease (CMT) is an inherited periph-
eral neuropathy and the prevalence of the phenotype has
been determined to be 1:2500 in Western Norway and 1
per 1214 in South-eastern Norway (Akershus County)
[1,2]. Symptoms of the classical phenotype encompass dis-
tal limb weakness and muscular atrophy, tendon areflexia,
and sensory loss, most noticeable in the legs. Foot deform-
ities like pes cavus and hammertoes are often found [3].
The first symptoms usually occur in the first or second dec-
ade and the physical impairments are mostly mild, and with
slow progression [4]. The nerve conduction velocity in the
median motor nerve (MNCV) is measured to differentiate
between the autosomal dominant demyelinating type 1 and
the autosomal dominant axonal type 2 (CMT1 < 38 m/s <
CMT2). Intermediate forms of CMT are characterized by
relatives with MNCVs in both ranges due to both demye-
linating and axonal pathology [5]. Autosomal recessive
forms (CMT4), and X-linked forms (CMTX) are designated
by the inheritance pattern, independent of NCS results.
Within each CMT category subclasses are determined by
the disease associated gene or locus, and more than 40
CMTassociated genes and loci have been identified [6].
More than 90% of the mutations detected in a diag-
nostic setting are constituted by a PMP22dup, or a se-
quence variant in the MPZ or the MFN2 gene, causing
autosomal dominant CMT, or a mutation in the GJB1
gene, causing X-linked CMT [7-9]. Patients with a dupli-
cation of the PMP22 region develop a classical CMT
phenotype in most cases, but the phenotype is also charac-
terized by inequality in severity, even between close rela-
tives [10]. The median MNCV is always < 38 m/s [10-13].
Patients with MPZ mutations may have a grave demye-
linating phenotype, Dejerine-Sottas syndrome/CMT3
(DSS, MIM 145900) or congenital hypomyelinating
neuropathy (MIM 605253) with very slow MNCVs or
they may have a milder CMT1 or CMT2 phenotype
with MNCVs in the intermediate or axonal range [14].
MFN2 mutations may be coupled with the classical
CMT2 phenotype, but individuals who experience an early
disease onset (<10 years) also tend to have severe symp-
toms, sometimes also optic atrophy [15,16]. Males with a
GJB1 mutation typically have a more severe phenotype
than females, and mostly demonstrate MNCVs in the de-
myelinating or intermediate range, whereas females com-
monly are asymptomatic or mildly affected, with MNCVs
in the intermediate or axonal range [17].
Relatives of index patients with a documented sequence
variant may request genetic counselling and testing. The
requests for testing of family members fall within four
categories: diagnostic, prenatal, and presymptomatic test-
ing of family members for certain or likely pathogenic
variants, and finally, carrier testing/segregation analysis
of relatives for the investigation of genetic variants ofunknown clinical significance. This study is founded upon
a previous report on diagnostic testing, the index patients
of this study are described in detail there [9]. The main
objective of this study was to make a further assessment of
the family investigations performed as part of the evalu-
ation of genetic variants of unknown clinical significance
(VUS). We included 87 family members of 41 index pa-
tients. Here we provide an overview of the indications for
testing, the distribution of relatives under each category as
well as the test outcome. We believe that these results will
aid in estimating and planning the extent of resources
required for the various aspects of family evaluations in
CMT performed by diagnostic laboratories. Finally, the re-
sults presented show that clinical evaluation alone is not




Between 2004 and 2010, 435 index patients underwent
diagnostic testing for CMT and 72 genetic variants of
either definite, likely or uncertain pathogenicity were iden-
tified [9]. Subsequent molecular genetic family investiga-
tions were requested for 31 families (43%) harbouring
PMP22dup (6) or mutations in GJB1 (12), MPZ (7),
MFN2 (5) and NEFL (1) (Table 1). All mutations were
suspected to invoke autosomal dominant or X-linked
(GJB1) inheritance. For completeness, four individual
samples received in 2002 and 2003 were included be-
cause their extended families were investigated during
the years 2004–2010. In addition, we received samples
from 12 relatives of 10 index cases with PMP22 dupli-
cations (9), and a GJB1 mutation causing p.Arg183Cys,
diagnosed in other laboratories. In total, requests for test-
ing of 87 family members from 41 families were received







Figure 1 The quantitative, clinical and genetic characterization of the relatives tested for known family mutations. (A) The annual
number of samples received for family investigations of known genetic variants from 2004–2010. For completeness, 4 individual samples received
2002–2003 were included because their families were otherwise investigated 2004–2010. (B) The indications for molecular genetic testing, and
the number of relatives within the 41 families. (C) The gene variants and number of affected relatives who tested positive within the 26 families.
(D) Clinical details reported in association with positive testing of affected family members. Group1: Polyneuropathy/CMT without further
specifications. Group 2: Detailed description of a classical CMT phenotype. Group 3: As 2, but more severe. Group 4: As in 2, but with additional
features that may be seen in association with the investigated genes. Group 5: Description of a phenotype with symptoms that are atypical for
the CMT phenotype. (E) Age at presymptomatic testing in relation to positive and negative findings. (F) Age at testing in family studies of
uncertain variants and the proportion of healthy and affected relatives.
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A Genovision M48 (Qiagen) or Biorobot EZ-1 (Qiagen)
system was used to extract DNA from peripheral blood
cells. Relatives were tested for the specific mutation
previously identified in the index patient. Quantitativealterations of the PMP22 region were assessed by amp-
lification (SALSA MLPA KIT P033-B2 CMT1, MRC
Holland, Amsterdam). The Applied Biosystems 3130xl
Genetic Analyzer performed the fragment analysis of
PCR products. DNA sequencing of the MPZ, GJB1,
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tron sequences were performed as described in Østern
et al., 2013 [9].
Data collection, statistics and endpoint measures
The data sampled from the requisitions and analyzed
with the Statistical Package for the Social Sciences (SPSS)
version 20.0 included: the sample year and test indication
(diagnostic, presymptomatic, carrier, prenatal), clinical
details and results on NCS, the age at onset and age at
testing, the number of genetically verified affected re-
latives, the gender of the index patient as well as their
relatives, whether or not the mutation was found, and
if yes, the name of the gene/mutation and the inter-
pretation of its consequences. The NCS results were
classified as demyelinating, axonal, or mixed demyelin-
ating and axonal. The clinical details were divided into:
1: Requests for CMT testing without relevant comple-
mentary clinical details, 2: Clinical details supportive
of a classical CMT phenotype, 3: As in 2, but signifi-
cantly more severe, 4: As in 2, but with supplemental
traits known to be associated with the genes under
investigation (such as tremor, sensorineural hearing
impairment), 5: A polyneuropathy phenotype that is
atypical for hereditary sensorimotor neuropathy (e.g.
HSN-like, HMN-like, prominent upper limb symp-
toms). (Further details have been published previously
[9]). The Alamut software (Interactive Biosoftware,
San Diego, CA, USA) and literature studies were used
to judge the clinical relevance of the genetic variants.
The variants were classified in compliance with the
proposal from The IARC Unclassified Genetic Variants
Working Group; 5 = definitely pathogenic, 4 = likely
pathogenic, 3 = uncertain, 2 = likely not pathogenic, 1
= definitely not pathogenic [18]. Class 3–5 variants
were defined as positive findings in this study, whereas
class 1–2 variants were defined as negative findings.
With the exception of diagnostic testing, genetic inves-
tigations were performed after genetic counselling. Fol-
low up studies of class 3 variants were performed with
standard methods, including carrier testing of family
members, paternity testing and investigation of control
samples [19]. The reclassification of a sequence variant
was defined as the adjustment of the interpretation from
class 3, to class 2 or 4 after extended investigations.
Diagnostic, prenatal, and presymptomatic testing was
offered for genetic variants of definite or likely clinical
relevance (class 4 and 5).
The study was approved by the Norwegian Data
Inspectorate and the Regional Committee for Medical
Research Ethics who specified that it was not necessary
with informed consent given by subjects/next-of-kin
for this study. Procedures were in accordance with the
revised Helsinki Declaration of 2008.Results
The average number of family members for whom genetic
tests were requested was 2.1 per index case (range 1–6).
When the laboratory identified a PMP22 dup- in an index
patient, it subsequently received samples of relatives for
testing in 23% of the cases. The corresponding percent-
ages for cases harbouring sequence variants in GJB1, MPZ
and MFN2 were 60%, 64% and 42%, respectively. The
indications for molecular genetic testing in the various
families and individual family members are illustrated in
Figure 1B. In total, 41 positive molecular genetic findings
were made (67.2%) in 61 relatives tested for likely or cer-
tain pathogenic variants. Furthermore, in three family
members and in three index patients from three families,
class 3 mutations were upgraded to class 4.
Diagnostic testing of affected family members for definite
or likely pathogenic genetic variants (class 5 and class 4)
Diagnostic testing was performed in 41 affected relatives
from 29 families with class 5 or class 4 mutations. Six af-
fected relatives (14.6%), three from families with PMP22
duplications, one harbouring an MPZ mutation and two
with GJB1 mutations, tested negative. NCS results were
reported as normal in two and were unspecified in four.
For all six, “polyneuropathy” or “CMT” was the only
clinical information reported. Age at onset was specified
in three cases (5–10, 30–40, 40–50 years), and age at
testing was 8, 15, 36, 38, 46 and 54 years respectively.
Thirty-five affected relatives, from 26 families, tested
positive for class 4/5 mutations identified in the corre-
sponding index patent (Figure 1C). Average age at testing
was 27.6 years (range 2 months – 78 years). NCS results
were reported only in 28.6% of the affected relatives.
Only scarce clinical information was given for 65.7%
of the affected relatives; such as “polyneuropathy” or
“CMT” (clinical group 1) (Figure 1D). The remaining ma-
jority (22.9%) had specified a classical CMT phenotype
(clinical group 2). In a family with an MPZ mutation two
patients were classified as severe (clinical group 3) and one
as atypical (clinical group 5). This family harboured a
c.368C >A (p.Gly123Val) substitution in the MPZ gene.
The index mother and two of her sons had Dejerine-Sottas
syndrome, and a daughter was admitted to the intensive
care unit with hypotonia and respiratory difficulties at the
age of two months. Another exception was a 42 year old
female with CMT and a c.490C >T (p.Arg164Trp) muta-
tion in the GJB1 gene who had tremor from early child-
hood, particularly of the head, muscular cramps and
fasciculation’s (clinical group 4). The MFN2 sequence vari-
ant, c.653 T >C (p.Leu218Pro), was identified in a mother
and her 16 year old son with CMT2 [9]. They had an ex-
tensive family history of polyneuropathy; however, other
family members were not available for testing. The p.
Leu218Pro residue is situated in the important GTPase
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and was interpreted as a class 4 variant based on in silico
analyses.
Presymptomatic testing of healthy family members for
definite or likely pathogenic genetic variants (class 5
and class 4)
Presymptomatic testing was performed in 20 healthy rel-
atives from 12 families with class 5 or class 4 mutations.
Average age at testing was 37.0 years (range 2 – 92
years, Figure 1E). In six minors, aged 15 or younger, for
whom NCS data were not available, one PMP22dup and
two GJB1 mutations were detected. In 14 relatives, aged
16 years or older, two with normal NCS results and 12
for whom NCS results were lacking, one PMP22dup and
two GJB1 mutations were detected.
Relatives included in the control group for the
assessment of genetic variants of unknown clinical
significance documented in the index patient (class 3)
In order to evaluate genetic variants of unknown signifi-
cance carrier testing and segregation analyses were car-
ried out in 22 relatives from eight families. Of nine
clinically affected relatives NCS results were available for
three (Figure 1F). Average age at testing was 44.7 years
(range 3 – 66 years). The patients were older than 30
years with the exception of two cases, a three year old
affected girl was tested for a c.410G > A (p.Gly137Asp)
mutation in the MPZ gene, and a 12 year old affected
girl was tested for a c.2146_2148 dup (p.Ala716dup)
mutation in the MFN2 gene. Eight class 3 sequence vari-
ants, and their secondary classification after family studies,Table 2 Class 3 sequence variants not reported in the HGMDp
and secondary classification after family studies




MFN2 1* c.250 A > G p.Lys84Glu 2 0
2 c.1709 A > G p.Asn570Ser 4 1
3* c.2146_2148 dup p.Ala716dup 3 1
4* c.692C > T p.Ser231Phe 2 0
MPZ 1* c.410 G > A p.Gly137Asp 3 3
2 c.103 G > A p.Asp35Asn 3 2€
3* c.368 G > T p.Gly123Val 5 2
NEFL 1* c.1027_1029del p.Asp343del 1 1
†In addition to index.
$Primary classification of genetic variants in the index patient in accordance with th
Group; 4 = likely disease causing, 3 = uncertain, 2 = likely not disease causing [18].
£Secondary classification of genetic variants after extended family investigations.
*Sequence variants reported in a previous work [9].
‡Parents negative, de novo mutation in the first following generation. MFN2 family 1
control chromosomes. Paternity was genetically verified.
¶This variant was later reported with a possible association to dHMN in a single No
€One affected carrier remotely related to an index patient identified in 2012; not inare listed in Table 2. After segregation studies the classifi-
cation of mutation pathogenicity was upgraded from class
3 to class 4 for two independent MFN2 mutations as they
showed to have occurred de novo in one isolated case of
CMT2 and in a patient with an affected carrier child. One
MFN2 mutation was downgraded from class 3 to class 2
since it was also detected in two healthy family members
aged 36 and 65 years. Finally, one MPZ mutation could be
upgraded from class 3 to class 4 after the detection of the
same mutation in an affected person remotely related to
an index patient.
Altogether three cases of de novo MFN2 mutations
were identified [9]. The first index patient, harbouring a
de novo c.2146_2148dup (p.Ala716dup) mutation, had
normal motor development up to the age of eight years.
The patient then had a slowly progressing polyneurop-
athy with development of pes cavus and hammertoes.
At the age of 35 the patient had bilateral drop foot, and
was still fully employed. The child of the patient was in-
vestigated clinically at the age of three due to parental
concerns, but was without muscular weakness at the
time of assessment. However, NCS and EMG performed
six months later were compatible with axonal polyneur-
opathy. The second patient with a de novo c.692C > T
(p.Ser231Phe) substitution in the MFN2 gene had a
clinical development similar to that of the index patient
with the c.2146_2148dup mutation. The third de novo
mutation, a c.250A > G (p.Lys84Glu) substitution in the
MFN2 gene, was identified in a 12 year old child with
severe mixed (axonal and demyelinating) polyneurop-
athy, scoliosis, contractures, respiratory difficulties and
encephalopathy. None of the patients had optic atrophy.database or other sources at the time of identification,




0 0 2‡ 3 3
0 2 1 3 2¶
0 0 2‡ 3 4
0 0 2‡ 3 4
0 0 0 3 3
0 0 1 3 4
0 0 3 3 3
0 0 0 3 3
e recommendations from the IARC Unclassified Genetic Variants Working
; ongoing investigation, MFN2 family 3 and 4; mutation not found in 200
rwegian patient [24].
cluded in the total material.
Østern et al. BMC Medical Genetics 2014, 15:12 Page 6 of 7
http://www.biomedcentral.com/1471-2350/15/12Prenatal testing
Nine female carriers at fertile age (21–42 years) were car-
riers of class 5 variants. Prenatal testing was requested in
one case.
Discussion
In our experience clinicians and diagnostic laboratories
have a low threshold for requesting/carrying out diag-
nostic testing of relatives with polyneuropathy. Accord-
ingly, mutations were not identified in all affected family
members (85.4%). This may in part relate to the fact that
NCS results were available only for a minority (28.6%).
One might anticipate a wider phenotypic spectrum
among affected relatives as compared to index patients.
However, this was not the case in the material presented
here. Additional tremor and fasciculation’s, as reported
in a patient with a GJB1 mutation, or hypotonia and
possibly a severe phenotype, as reported in an infant
from a DSS family with a MPZ mutation, is within the
known range of phenotypes. For the remaining affected
relatives symptoms of classical CMT were reported.
Mild symptoms were reported in two out of three cases
with de novo mutation in MFN2, and age at onset < 10
years of age, whereas the third patient had a phenotype
more in accordance with the early onset group, as it is
described elsewhere [15,16,20]. Thus, the phenotypes de-
scribed in this cohort of affected relatives rather show a
tendency towards the mild end of the spectrum, particu-
larly in those carrying MFN2 mutations.
Presymptomatic testing of adult family members gave a
detection rate (21%) well below 50%. This might be ex-
plained by the high mean age at testing (37.0 years), cases
of de novo mutations and the inclusion of second degree
relatives (3). De novo mutations in GJB1 are assumed to
be rare [21]. Minors constituted 30% (6/20) of the pre-
symptomatic group in this material. Five patients had an
affected parent, one an affected half sibling. Three of these
patients showed a positive genetic test result.
Family investigations and segregation analyses are
performed when genetic variants of uncertain clinical
relevance (class 3) are revealed and in some cases, inter-
pretations can be modified into class 1/2 or class 4/5,
permitting more accurate advice in genetic counselling.
Although the families described here are small, they
sometimes have the power to weaken the suspicion of
pathogenicity. The reclassification of variants identified
in nuclear families is mostly achieved in isolated cases
through the documentation of a de novo mutation in a
known CMT associated gene [19]. In four of the eight
families with class 3 variants interpretations were ad-
justed, three of them to class 4, of which two harbored
de novo mutations in the MFN2 gene (Table 2). Numer-
ous de novo MFN2 mutations have been reported in
several cohorts with severe symptoms, and some MFN2mutations, for example c.280C > T, have also been re-
ported as de novo multiple times [15,16,22,23]. Our results
therefore add to the data indicating that de novo MFN2
mutations are regularly found even in patients with a clas-
sical CMT2 phenotype [24].
When selecting healthy relatives for segregation analysis
older individuals are preferred. The mean age at testing
was higher in this group (44.7 years), as compared to the
presymptomatic (37.0 years) and diagnostic (28.4 years)
groups. An earlier CMT report indicated that many pa-
tients, and family members at risk, are uneducated about
the possibility of genetic counselling and genetic testing
[25]. We do not know to which extent this applies for the
cohort presented here, but we do see that significantly
more relatives are tested pr. index patient in the group in-
cluded for segregation analysis (2.7), as compared to the
presymptomatic (1.7) and diagnostic (1.4) groups. This
probably reflects the more active role of the laboratory in
the recruitment of relatives for the investigation of class 3
variants.
Prenatal diagnosis is available in most cases with
known class 5 or class 4 variants. In this series only 1/9
women in fertile age requested prenatal testing. Previ-
ously we have reported 72 index patients with CMT as-
sociated mutations, including 15 females with class 4/5
variants between the age of 20 and 46 years, of whom
none asked for prenatal testing at pregnancy [9]. Thus,
in our experience, Norwegian female carriers of CMT
associated mutations rarely make use of prenatal
diagnostics.
Conclusion
The results presented here clearly demonstrate that the
precise diagnosis of affected family members should rely
on the combination of NCS and genetic test results, not
clinical assessment alone. This particularly applies for
the investigation of the clinical significance of class 3
variants. They are coupled with uncertainties that often
prevail in spite of meticulous family investigations. The
implementation of next generation sequencing technolo-
gies in the diagnostic testing of index patients leads to
an increase in the already large proportion of class 3
variants. Hence, there is a need for genetic counselling
capacity and expertise to be scaled up accordingly to
maintain a proportionate relationship between the cap-
acity for diagnostic testing of index patients and the sub-
sequent investigations of their families.
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